MCL1 and melanoma: The data presented herein clearly provide the first evidence that the use of Mcl-1 inhibitor – MIM1 contributes to the loss in the amelanotic melanoma cells viability, GSH depletion and DNA fragmentation which indicates that the tested Mcl-1 inhibitor exhibits high antitumor activity towards melanoma cells.